Omer A. Donmez

Enhanced EBNA2-dependent activity in EBV-transformed B cells from patients with multiple sclerosis

This study shows that EBNA2 activity is increased in MS patients, altering gene expression and chromatin accessibility in EBV-transformed B cells.

Comparison of PU.1 genomic binding across immune cells reveals cell type-specific roles in autoimmune disease

Global Evaluation of Congenital Heart Disease-Associated Non-Coding Variants

This study evaluates over 3,000 congenital heart disease-risk variants using SNP Bind-n-Seq and MPRA to identify variants with allelic TF binding and regulatory activity.

Ddx3x regulates B-cell development and immunoglobulin rearrangement in mice

This study shows that Ddx3x is essential for B-cell development in mice, with loss leading to developmental blocks and defects in immunoglobulin rearrangement.

Macrophage epigenetic memories of early life injury drive neonatal nociceptive priming

This study shows that macrophage epigenetic changes from early life injury influence pain responses later in life, with a focus on sex-specific effects.

maxATAC: genome-scale transcription-factor binding prediction from ATAC-seq with deep neural networks

maxATAC provides deep learning models for predicting transcription factor binding sites from ATAC-seq data, improving prediction in primary and single-cell contexts.

Epigenetic and Transcriptional Dysregulation in CD4+ T cells of Patients with Atopic Dermatitis

This study identifies epigenetic and transcriptional dysregulation in CD4+ T cells of atopic dermatitis patients, linking genetic risk variants to altered chromatin accessibility and NFKB1 binding.

Epstein-Barr virus nuclear antigen 2 (EBNA2) extensively rewires the human chromatin landscape at autoimmune risk loci

This study shows EBNA2 alters chromatin structure and gene expression at autoimmune risk loci, linking viral infection to genetic risk mechanisms in autoimmune diseases.

Genome-wide discovery of lupus genetic risk variant allelic regulatory activity

The paper identifies 482 SLE risk variants with enhancer activity and characterizes allelic regulatory mechanisms at 27 risk loci using MPRA.